Associations between osteoporosis and drug exposure: A post-marketing study of the World Health Organization pharmacovigilance database (VigiBase®)

被引:11
|
作者
Batteux, Benjamin [1 ,2 ,3 ,4 ]
Bennis, Youssef [1 ,3 ]
Bodeau, Sandra [1 ,3 ]
Masmoudi, Kamel [1 ]
Hurtel-Lemaire, Anne-Sophie [1 ]
Kamel, Said [3 ,5 ]
Gras-Champel, Valerie [1 ,3 ]
Liabeuf, Sophie [1 ,3 ]
机构
[1] Amiens Univ, Dept Pharmacol, Med Ctr, F-80054 Amiens, France
[2] St Quentin Med Ctr, Dept Rheumatol, F-02321 St Quentin en Yvelines, France
[3] Jules Verne Univ Picardie, MP3CV Lab, EA7517, F-80054 Amiens, France
[4] Amiens Picardie Univ, RECIF, Med Ctr, F-80054 Amiens, France
[5] Amiens Univ, Biochem Lab, Med Ctr, F-80000 Amiens, France
关键词
Osteoporosis; Drug; Pharmacology; Pharmacoepidemiology; Pharmacovigilance; BONE-MINERAL DENSITY; RHEUMATOID-ARTHRITIS PATIENTS; LOW-DOSE METHOTREXATE; POSTMENOPAUSAL WOMEN; FRACTURE RISK; VITAMIN-A; PSYCHOTROPIC MEDICATIONS; INADEQUATE RESPONSE; MULTIPLE-SCLEROSIS; SIGNAL GENERATION;
D O I
10.1016/j.bone.2021.116137
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Bone remodeling is a complex process, and many conditions (including drug exposure) lead to osteoporosis. Here, we sought to detect new disproportionality signals for drugs associated with osteoporosis. Methods: We performed a disproportionality analysis of the World Health Organization's VigiBase (R) pharmacovigilance database through April 12, 2020. The frequency of reports on osteoporosis for all identified drug classes was compared with that for all other drugs and quoted as the reporting odds ratio (ROR) [95% confidence interval (CI)]. Results: Of the 7,594,968 cases spontaneously recorded to VigiBase (R), 4758 concerned osteoporosis. New disproportionality signals with a pharmacologically plausible mechanism were found for drugs used in neurology (levodopa (ROR [95%CI]: 10.18 [4.33-25.10]), selective serotonin agonists (4.22 [2.34-7.00]) and memantine (4.10 [1.56-8.93])), hematology (romiplostim (4.93 [1.15-21.10])), pulmonology (macitentan (3.02 [1.84-4.90])), ophthalmology (ranibizumab (3.31 [1.00-10.51])) and rheumatology (tofacitinib (3.65 [3.00-4.40])). The robustness of these new results is supported by the significant RORs for the vast majority of drugs already known to induce osteoporosis and/or increase the fracture risk, namely glucocorticoids, gonadotropin-releasing hormone analogs, anti-aromatases, androgen receptor blockers, thyroid hormones, proton pump inhibitors, thiazolidinediones, vitamin K antagonists, loop diuretics, protease inhibitors, nucleoside and nucleotide reverse transcriptase inhibitors, and enzyme-inducing antiepileptics including barbiturates and derivatives, hydantoin derivatives, carboxamide derivatives and fatty acid derivatives. Conclusion: We established up a comprehensive list of drugs potentially associated with osteoporosis and highlighted those with pharmacologically plausible mechanisms leading to bone fragility. Our results might pave the way for additional exploration of these mechanisms.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Associations between osteoporosis and drug exposure: A post-marketing study of the World Health Organization pharmacovigilance database (VigiBase®)
    Batteux, B.
    Bennis, Y.
    Bodeau, S.
    Masmoudi, K.
    Hurtel-Lemaire, A. S.
    Kamel, S.
    Gras-Champel, V.
    Liabeuf, S.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2022, 36 : 159 - 159
  • [2] Associations between Th1-mediated diseases and omalizumab: A post-marketing study of the World Health Organization pharmacovigilance database (VigiBase®)
    Magnifico, S.
    Dernoncourt, A.
    Masmoudi, K.
    Liabeuf, S.
    Gras-Champel, V.
    Batteux, B.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2022, 36 : 14 - 15
  • [3] Safety of selinexor as the only exportin 1 (XPO1) inhibitor so far: a post-marketing study based on the world Health Organization pharmacovigilance database (Vigibase)
    Chen, Chenxin
    Miao, Xiaoyong
    Guo, Xiaojing
    Xu, Jinfang
    Liang, Jizhou
    Zheng, Yi
    Chi, Lijie
    Chen, Xiao
    Wei, Lianhui
    Zhang, Hewei
    Ye, Xiaofei
    He, Jia
    EXPERT OPINION ON DRUG SAFETY, 2023,
  • [4] Safety of selinexor as the only exportin 1 (XPO1) inhibitor so far: a post-marketing study based on the world Health Organization pharmacovigilance database (Vigibase)
    Chen, Chenxin
    Miao, Xiaoyong
    Guo, Xiaojing
    Xu, Jinfang
    Liang, Jizhou
    Zheng, Yi
    Chi, Lijie
    Chen, Xiao
    Wei, Lianhui
    Zhang, Hewei
    Ye, Xiaofei
    He, Jia
    EXPERT OPINION ON DRUG SAFETY, 2024, 23 (02) : 247 - 255
  • [5] Safety of selinexor as the only exportin 1 (XPO1) inhibitor so far: a post-marketing study based on the world Health Organization pharmacovigilance database (Vigibase)
    Chen, Chenxin
    Miao, Xiaoyong
    Guo, Xiaojing
    Xu, Jinfang
    Liang, Jizhou
    Zheng, Yi
    Chi, Lijie
    Chen, Xiao
    Wei, Lianhui
    Zhang, Hewei
    Ye, Xiaofei
    He, Jia
    EXPERT OPINION ON DRUG SAFETY, 2024, 23 (02) : 247 - 255
  • [6] Antidepressants and Movement Disorders: A post-marketing study in the world pharmacovigilance database
    Revet, A.
    Montastruc, F.
    Roussin, A.
    Raynaud, J. P.
    Lapeyre-Mestre, M.
    Nguyen, T. T. H.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2021, 35 : 97 - 98
  • [7] Post-marketing drug safety surveillance of enfortumab vedotin: an observational pharmacovigilance study based on a real-world database
    Yu, Mingming
    Zhou, Lijun
    Cao, Mengda
    Ji, Chunmei
    Zheng, Yuanyi
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [8] Post-marketing safety of panitumumab: a real-world pharmacovigilance study
    Wen, Heli
    Lei, Yuqing
    Mao, Lingjie
    EXPERT OPINION ON DRUG SAFETY, 2024,
  • [9] Safety Profile of Sclerosing Agents: An Analysis From the World Health Organization Pharmacovigilance Database VigiBase
    Roselli, Audrey
    Khouri, Charles
    Roustit, Matthieu
    Blaise, Sophie
    Cracowski, Jean-Luc
    DERMATOLOGIC SURGERY, 2019, 45 (12) : 1517 - 1528
  • [10] Safety profile of sclerosing agents: an analysis from the world health organization pharmacovigilance database VigiBase®
    Khouri, C.
    Roselli, A.
    Roustit, M.
    Blaise, S.
    Cracowski, J. L.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2018, 32 : 53 - 53